Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Population pharmacokinetics and pharmacodynamics of the artesunate-mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children.

Guidi M, Mercier T, Aouri M, Decosterd LA, Csajka C, Ogutu B, Carn G, Kiechel JR.

Malar J. 2019 Apr 18;18(1):139. doi: 10.1186/s12936-019-2754-6.

2.

Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial.

Sirima SB, Ogutu B, Lusingu JPA, Mtoro A, Mrango Z, Ouedraogo A, Yaro JB, Onyango KO, Gesase S, Mnkande E, Ngocho JS, Ackermann I, Aubin F, Vanraes J, Strub N, Carn G.

Lancet Infect Dis. 2016 Oct;16(10):1123-1133. doi: 10.1016/S1473-3099(16)30020-2. Epub 2016 Jul 16.

3.

Fixed dose artesunate amodiaquine - a phase IIb, randomized comparative trial with non-fixed artesunate amodiaquine.

Ogutu B, Juma E, Obonyo C, Jullien V, Carn G, Vaillant M, Taylor WR, Kiechel JR.

Malar J. 2014 Dec 16;13:498. doi: 10.1186/1475-2875-13-498.

4.

Strengthening neglected tropical disease research through enhancing research-site capacity: an evaluation of a novel web application to facilitate research collaborations.

Furtado T, Franzen S, van Loggerenberg F, Carn G, Grahek S, McBride M, Power M, O'Reilly J, Savarese B, Snowden MA, Stevens G, Uys A, Lang T.

PLoS Negl Trop Dis. 2014 Nov 13;8(11):e3225. doi: 10.1371/journal.pntd.0003225. eCollection 2014 Nov. No abstract available.

5.

Efficacy of artesunate-amodiaquine and artemether-lumefantrine fixed-dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria among children aged six to 59 months in Nimba County, Liberia: an open-label randomized non-inferiority trial.

Schramm B, Valeh P, Baudin E, Mazinda CS, Smith R, Pinoges L, Dhorda M, Boum Y 2nd, Sundaygar T, Zolia YM, Jones JJ, Comte E, Houzé P, Jullien V, Carn G, Kiechel JR, Ashley EA, Guérin PJ.

Malar J. 2013 Jul 17;12:251. doi: 10.1186/1475-2875-12-251.

6.

Tolerability and safety of artesunate-amodiaquine and artemether-lumefantrine fixed dose combinations for the treatment of uncomplicated Plasmodium falciparum malaria: two open-label, randomized trials in Nimba County, Liberia.

Schramm B, Valeh P, Baudin E, Mazinda CS, Smith R, Pinoges L, Sundaygar T, Zolia YM, Jones JJ, Comte E, Bruneel A, Branger M, Jullien V, Carn G, Kiechel JR, Ashley EA, Guérin PJ.

Malar J. 2013 Jul 17;12:250. doi: 10.1186/1475-2875-12-250.

7.

Population pharmacokinetics and pharmacodynamic considerations of amodiaquine and desethylamodiaquine in Kenyan adults with uncomplicated malaria receiving artesunate-amodiaquine combination therapy.

Jullien V, Ogutu B, Juma E, Carn G, Obonyo C, Kiechel JR.

Antimicrob Agents Chemother. 2010 Jun;54(6):2611-7. doi: 10.1128/AAC.01496-09. Epub 2010 Apr 5.

8.

Chloride channel 7 (ClCN7) gene mutations and autosomal dominant osteopetrosis, type II.

Waguespack SG, Koller DL, White KE, Fishburn T, Carn G, Buckwalter KA, Johnson M, Kocisko M, Evans WE, Foroud T, Econs MJ.

J Bone Miner Res. 2003 Aug;18(8):1513-8.

9.

Sibling pair linkage and association studies between peak bone mineral density and the gene locus for the osteoclast-specific subunit (OC116) of the vacuolar proton pump on chromosome 11p12-13.

Carn G, Koller DL, Peacock M, Hui SL, Evans WE, Conneally PM, Johnston CC Jr, Foroud T, Econs MJ.

J Clin Endocrinol Metab. 2002 Aug;87(8):3819-24.

PMID:
12161516
10.

Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23.

White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ.

Kidney Int. 2001 Dec;60(6):2079-86.

11.

The autosomal dominant hypophosphatemic rickets (ADHR) gene is a secreted polypeptide overexpressed by tumors that cause phosphate wasting.

White KE, Jonsson KB, Carn G, Hampson G, Spector TD, Mannstadt M, Lorenz-Depiereux B, Miyauchi A, Yang IM, Ljunggren O, Meitinger T, Strom TM, Jüppner H, Econs MJ.

J Clin Endocrinol Metab. 2001 Feb;86(2):497-500.

PMID:
11157998
12.

A 356-Kb sequence of the subtelomeric part of the MHC Class I region.

Hampe A, Coriton O, Andrieux N, Carn G, Lepourcelet M, Mottier S, Dréano S, Gatius MT, Hitte C, Soriano N, Galibert F.

DNA Seq. 1999;10(4-5):263-99.

PMID:
10727083
13.

Haemochromatosis and HLA-H.

Jouanolle AM, Gandon G, Jézéquel P, Blayau M, Campion ML, Yaouanq J, Mosser J, Fergelot P, Chauvel B, Bouric P, Carn G, Andrieux N, Gicquel I, Le Gall JY, David V.

Nat Genet. 1996 Nov;14(3):251-2. No abstract available.

PMID:
8896550
14.

Structural analysis of the HLA-A/HLA-F subregion: precise localization of two new multigene families closely associated with the HLA class I sequences.

Pichon L, Carn G, Bouric P, Giffon T, Chauvel B, Lepourcelet M, Mosser J, Legall JY, David V.

Genomics. 1996 Mar 1;32(2):236-44.

PMID:
8833150
15.

Cloning of a human homologue of the mouse Tctex-5 gene within the MHC class I region.

Giffon T, Lepourcelet M, Pichon L, Jezequel P, Bouric P, Carn G, Pontarotti P, Gall JY, David V.

Immunogenetics. 1996;44(5):331-9.

PMID:
8781118
16.

A new non-HLA multigene family associated with the PERB11 family within the MHC class I region.

Pichon L, Hampe A, Giffon T, Carn G, Legall JY, David V.

Immunogenetics. 1996;44(4):259-67.

PMID:
8753856
17.

Physical map of the HLA-A/HLA-F subregion and identification of two new coding sequences.

Pichon L, Giffon T, Chauvel B, Carn G, Bouric P, El Kahloun A, Legall JY, David V.

Immunogenetics. 1996;43(4):175-81.

PMID:
8575815

Supplemental Content

Support Center